{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104347","form_type":"8-K","ticker":"ALUR","cik":"0001964979","company_name":"ALLURION TECHNOLOGIES, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.714184+00:00","generated_at":"2026-05-17T18:28:51.347630+00:00","sec_items":["2.02","2.05","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Allurion cuts ~65% workforce, reports preliminary Q2 revenue ~$3M, shifts to GLP-1 combo therapy","bullets":["Preliminary Q2 2025 revenue ~$3M, operating loss ~$7M, improved from $9.3M loss in Q2 2024; operating expenses down ~50% YoY.","Restructuring: workforce reduction of ~70 employees (~65% of total); estimated severance charges of ~$1.5M; completion expected by end of Q3 2025.","Signed term sheet with strategic partner for ex-US distribution and potential joint development of a GLP-1 drug-eluting intragastric balloon.","Submitted protocol to IRBs for prospective study on low-dose GLP-1 + Allurion Program for weight loss and muscle preservation; enrollment expected in 2025.","PMA application for Allurion Balloon accepted by FDA for evaluation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104347","json":"https://secwatch.observer/filing/0000950170-25-104347.json","markdown":"https://secwatch.observer/filing/0000950170-25-104347.md","text":"https://secwatch.observer/filing/0000950170-25-104347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1964979/000095017025104347/0000950170-25-104347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1964979/000095017025104347/alur-20250804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:28:51.347630+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"028964e244f99ae8122529c6143a24bb720f60ab","claim":"ALLURION TECHNOLOGIES, INC. announced a restructuring with charges of approximately $1.5 million (approximately 70 employees, or approximately 65% of its workforce).","evidence_excerpt":"employees between August 4, 2025 and August 6, 2025. As part of this Restructuring Plan, the Company expects to incur severance and severance-related charges of approximately $1.5 million. The Company’s estimated restructuring charges is based on a number of assumptions. Actual results may differ materially and the Company may also incur other charges or cash","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1964979/000095017025104347/0000950170-25-104347-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.5 million"},{"label":"Headcount","value":"approximately 70 employees, or approximately 65% of its workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}